Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q3 2025
Cumberland Pharmaceuticals (CPIX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Cumberland Pharmaceuticals (CPIX) reported revenue of $8.3M for the third quarter 2025 (Q3 2025), -9% from a year earlier and -23% from the quarter before. Operating margin was -23.7%, net loss $1.9M (23.5% of revenue).
Cumberland Pharmaceuticals, Q3 2025: revenue $8.3M (-9% year over year), operating margin -23.7%, net loss $1.9M, operating cash flow $187K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.3M | -23% | -9% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | $187K | -78% | -61% |
| Free cash flow | $163K | -80% | -64% |
What changed
Revenue was $8.3M in Q3 2025, down 9% year over year and down 23% from the previous quarter. Sancuso was the largest line at 39% of revenue. Kristalose lost $2.5M year over year (down 67%), 309% of the total change.
Operating costs exceeded revenue by $2.0M, an operating margin of -23.7%. Total costs fell 5% while revenue fell 9%. The quarter ended with a net loss of $1.9M, wider than the previous quarter's $735K loss.
Operating cash flow was $187K (down 61% year over year). Non-cash charges added back $1.0M of depreciation and amortization and $81K of share-based compensation. Working capital and other items added $1.0M. Capital expenditures of $24K left free cash flow of $163K.
Questions
What was Cumberland Pharmaceuticals' revenue in the third quarter 2025?
Cumberland Pharmaceuticals (CPIX) reported revenue of $8.3M for the third quarter 2025 (Q3 2025), -9% from a year earlier and -23% from the quarter before.
Was Cumberland Pharmaceuticals profitable in the third quarter 2025?
Operating loss was $2.0M (-23.7% of revenue) and net loss $1.9M.